Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Archives of Dermatological Research
Published in: Archives of Dermatological Research 6/2016

Open Access 01-08-2016 | Review

The German National Program on Psoriasis Health Care 2005–2015: results and experiences

Authors: M. Augustin, L. Eissing, A. Langenbruch, A. Enk, T. Luger, D. Maaßen, U. Mrowietz, K. Reich, M. Reusch, K. Strömer, D. Thaçi , R. von Kiedrowski, M. A. Radtke

Published in: Archives of Dermatological Research | Issue 6/2016

Login to get access

Abstract

In 2005, the first national psoriasis survey in Germany revealed large deficits in health care particularly in patients with moderate to severe disease. The consecutive goal was to improve health care for psoriasis countrywide. For this, a large-scale national program was initiated starting with a comprehensive analysis of structures and processes of care for psoriasis. Patient burden, economic impact and barriers to care were systematically analyzed. In order to optimize routine care, a S3 guideline, a set of outcomes measures and treatment goals, were developed. Implementation was enforced by the German Psoriasis Networks (PsoNet) connecting the most dedicated dermatologists. The annual National Conference on Health Care in Psoriasis established in 2009 consented National Health Care Goals in Psoriasis 2010–2015 and defined a set of quality indicators, which are monitored on a regular basis. Currently 28 regional networks including more than 800 dermatologists are active. Between 2005 and 2014 7 out of 8 quality indicators have markedly improved, and regional disparities were resolved. e.g., mean PASI (Psoriasis Area Severity Index) dropped from 11.4 to 8.1 and DLQI (Dermatology Life Quality Index) from 8.6 to 5.9. A decade of experience indicates that a coordinated nationwide psoriasis program based on goal orientation can contribute to better quality of care and optimized outcomes.
Literature
1.
Augustin M (2008) PsoNet-more health care quality through regional psoriasis networks. J Dtsch Dermatol Ges 6(4):263–264CrossRefPubMed
2.
Augustin M, Alvaro-Gracia JM, Bagot M, Hillmann O, van de Kerkhof PCM, Kobelt G, Maccarone M, Naldi L, Schellekens H (2012) Psoriasis white paper—a framework for improving the quality of care for people with psoriasis. J Eur Acad Dermatol Venereol 26(Suppl 4):1–16CrossRefPubMed
3.
Augustin M, Chapnick J, Gupta S, Buesch K, Radtke M (2011) Psoriasis verursacht hohe Kosten, mindert die Produktivität am Arbeitsplatz und verringert die Lebensqualität. Akt Dermatol 37:353–359CrossRef
4.
Augustin M, Kaufmann R, Strömer K, Christophers E, von Zitzewitz H (eds) (2014) PsoNet Magazin, Hamburg
5.
Augustin M, Glaeske G, Radtke M, Christophers E, Reich K, Schaefer I (2010) Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 162:633–636CrossRefPubMed
6.
Augustin M, Glaeske G, Schaefer I, Rustenbach SJ, Hoer A, Radtke MA (2012) Processes of psoriasis health care in Germany—long-term analysis of data from the statutory health insurances. J Dtsch Dermatol Ges 10(9):648–655PubMed
7.
Augustin M, Herberger K, Hintzen S, Heigel H, Franzke N, Schäfer I (2011) Prevalence of skin lesions and need for treatment in a cohort of 90,880 workers. Br J Dermatol 165(4):865–873CrossRefPubMed
8.
Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K (2008) Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatol Basel Switz 216(4):366–372CrossRef
9.
Augustin M, Radtke MA, Glaeske G, Reich K, Christophers E, Schaefer I, Jacobi A (2015) Epidemiology and comorbidity in children with psoriasis and atopic eczema. Dermatology 231(1):35–40CrossRefPubMed
10.
Augustin M, Reich K, Blome C, Schäfer I, Laass A, Radtke MA (2010) Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 163(3):580–585CrossRefPubMed
11.
Augustin M, Reich K, Glaeske G, Kämpfe S, Radtke MA, Gerdau-Heitmann C, Schicktanz C, Schäfer I (2013) Drug supply for children with psoriasis in Germany. J Dtsch Dermatol Ges 11(8):751–755PubMed
12.
Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M (2010) Co-morbidity and age-related prevalence of psoriasis—analysis of health insurance data in Germany. Acta Derm Venereol 90(2):147–151CrossRefPubMed
13.
Augustin M, Reich K, Reich C, Purwins S, Rustenbach SJ, Schaefer I, Radtke M (2008) Quality of psoriasis care in Germany—results of the National Study PsoHealth 2007. J Dtsch Dermatol Ges 6(8):640–646CrossRefPubMed
14.
Augustin M, Reich K, Radtke M, Dierks C (2007) Lebensqualität, Compliance und Empowerment bei Psoriasis. UNI-MED Publisher, Boston
15.
Augustin M, Radtke MA, Zschocke I, Blome C, Behechtnejad J, Schäfer I, Reusch M, Mielke V, Rustenbach SJ (2009) The patient benefit index: a novel approach in patient-defined outcomes measurement for skin disease. Arch Dermatol Res 301(8):561–571CrossRefPubMed
16.
Augustin M, Reich K, Reusch M, Luger T, Franzke N, Schaefer I, Rustenbach SJ, Radtke MA (2009) Health services research in psoriasis—the German approach. Dermatology 218(4):293–301CrossRefPubMed
17.
Augustin M, Schaefer I, Reich K, Glaeske G, Radtke M (2011) Systemische Glukokortikosteroide bei Psoriasis—Versorgung jenseits der S3-Leitlinie. J Dtsch Dermatol Ges 9(10):833–839PubMed
18.
Augustin M, Spehr C, Radtke MA, Boehncke WH, Luger T, Mrowietz U, Reusch M, Strömer K, Wozel G, Rv Kiedrowski, Rustenbach SJ, Purwins S, Reich K (2014) German psoriasis registry PsoBest: objectives, methodology and first baseline data. J Dtsch Dermatol Ges 12(1):48–57PubMed
19.
Augustin M, Schadendorf D (2015) Nationale Versorgungskonferenz Hautkrebs 2015. Erste konstituierende Sitzung am 18.02.2015 in Hamburg. J Dtsch Dermatol Ges 13(7):730–731CrossRef
20.
Berger K, Ehlken B, Kugland B, Augustin M (2005) Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 3(7):511–518CrossRefPubMed
21.
Blome C, Augustin M, Behechtnejad J, Rustenbach SJ (2011) Dimensions of patient needs in dermatology: subscales of the patient benefit index. Arch Dermatol Res 303(1):11–17CrossRefPubMed
22.
Blome C, Simianer S, Purwins S, Laass A, Rustenbach SJ, Schaefer I, Radtke M, Augustin M (2010) Time needed for treatment is the major predictor of quality of life in psoriasis. Dermatology 221(2):154–159CrossRefPubMed
23.
24.
Der Berufsverband der Deutschen Dermatologen (BVDD), Deutsche Dermatologische Gesellschaft (DDG) (2015) PsoNet—Regionale Psoriasisnetze in Deutschland. Available via DIALOG. http://​www.​psonet.​de/​. Accessed 22 Sep 2015
25.
26.
27.
Eissing L, Radtke MA, Zander N, Augustin M (2015) Barriers to guideline-compliant psoriasis care: analyses and concepts. J Eur Acad Dermatol Venereol. doi:10.​1111/​jdv.​13452 PubMed
28.
29.
Feuerhahn J, Blome C, Radtke MA, Augustin M (2012) Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis. Arch Dermatol Res 304(6):433–441CrossRefPubMed
30.
Franzke N, Zimmer L, Schäfer I, Radermacher C, Kresken J, Augustin M (2009) Quality of medical care of patients with acne vulgaris in Germany—nationwide survey of pharmacy clients. J Dtsch Dermatol Ges 7(12):1060–1063PubMed
31.
Glaeske G, Augustin M, Abholz H, Banik N, Brüggenjürgen B, Hasford J, Hoffmann W, Kruse J, Lange S, Schäfer T, Schubert I, Trampisch H-J, Windeler J (2009) Epidemiological methods for health services research. Gesundheitswesen 71:685–693CrossRefPubMed
32.
33.
Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M (2010) Psoriasis: is the impairment to a patient’s life cumulative? J Eur Acad Dermatol Venereol 24(9):989–1004PubMed
34.
Koller M, Neugebauer EAM, Augustin M, Büssing A, Farin E, Klinkhammer-Schalke M, Lorenz W, Münch K, Petersen-Ewert C, Steinbüchel N, Wieseler B (2009) Die Erfassung von Lebensqualität in der Versorgungsforschung—konzeptuelle, methodische und strukturelle Voraussetzungen. Gesundheitswesen 71(12):864–872CrossRefPubMed
35.
Langenbruch AK, Radtke MA, Augustin M (2012) Quality of psoriasis care from the patients’ perspective—results of the National Health Care Study PsoReal. Eur J Dermatol 22(4):518–524PubMed
36.
Langenbruch A, Radtke MA, Jacobi A, Haack K, Reich K, Strömer K, Mrowietz U, Augustin M (2015) Quality of psoriasis care 2013/14/—results of the National Health Care Study “PsoHealth 3”. Arch Dermatol Res (in press)
37.
Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Daudén E, Gisondi P, Iversen L, Kemény L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N (2011) Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 303(1):1–10CrossRefPubMed
38.
Müller D, Augustin M, Banik N, Baumann W, Bestehorn K, Kieschke J, Lefering R, Maier B, Mathis S, Rustenbach SJ, Sauerland S, Semler SC, Stausberg J, Sturm H, Unger C, Neugebauer EA (2010) Memorandum Register für die Versorgungsforschung—memorandum registry for health services research. Gesundheitswesen 72(11):824–839CrossRefPubMed
39.
Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Sammain A, Schlaeger M, Sebastian M, Sterry W, Streit V, Augustin M, Erdmann R, Klaus J, Koza J, Muller S, Orzechowski HD, Rosumeck S, Schmid-Ott G, Weberschock T, Rzany B, Deutsche Dermatologische Gesellschaft (DDG), Berufsverband Deutscher Dermatologen (BVDD) (2012) S3—guidelines on the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 10(Suppl 2):S1–95CrossRef
40.
Ormerod AD, Augustin M, Baker C, Chosidow O, Cohen AD, Dam TN, Garcia-Doval I, Lecluse LL, Schmitt-Egenolf M, Spuls PI, Watson KD, Naldi L (2012) Challenges for synthesising data in a network of registries for systemic psoriasis therapies. Dermatology 224(3):236–243CrossRefPubMed
41.
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, Identification and Management of Psoriasis and Associated Comorbidity (IMPACT) project team (2013) Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 133(2):377–385CrossRefPubMed
42.
Radtke M, Augustin J, Blome C, Reich K, Rustenbach SJ, Schaefer I, Laass A, Augustin M (2010) How do regional factors influence psoriasis patient care in Germany? J Dtsch Dermatol Ges 8(7):516–524PubMed
43.
Radtke MA, Mrowietz U, Feuerhahn J, Härter M, von Kiedrowski R, Nast A, Reich K, Strömer K, Wohlrab J, Augustin M (2015) Early detection of comorbidity in psoriasis: recommendations of the National Conference on Health care in Psoriasis. J Dtsch Dermatol Ges 13(7): 674–690
44.
Radtke MA, Reich K, Blome C, Kopp I, Rustenbach SJ, Schaefer I, Augustin M (2009) Evaluation of quality of care and guideline-compliant treatment in psoriasis: development of a new system of quality indicators. Dermatology 219(1):54–58CrossRefPubMed
45.
Radtke MA, Reich K, Blome C, Rustenbach S, Augustin M (2009) Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 23(6):683–691CrossRefPubMed
46.
47.
Reich K, Krueger K, Moessner R, Augustin M (2009) Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 160(5):1040–1047CrossRefPubMed
48.
49.
Reich K, Mrowietz U, Radtke MA, Thaci D, Rustenbach SJ, Spehr C, Augustin M (2015) Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest. Arch Dermatol Res. doi:10.​1007/​s00403-015-1593-8
50.
Schäfer I, Rustenbach SJ, Radtke M, Augustin J, Glaeske G, Augustin M (2011) Epidemiology of psoriasis in Germany—analysis of secondary health insurance data. Gesundheitswesen 73(5):308–313CrossRefPubMed
51.
Schmid-Ott G, Malewski P, Kreiselmaier I, Mrowietz U (2005) Psychosocial consequences of psoriasis—an empirical study of disease burden in 3753 affected people. Hautarzt 56(5):466–472CrossRefPubMed
52.
Schöffski O, Augustin M, Prinz J, Rauner K, Schubert E, Sohn S, Reich K (2007) Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges 5(3):209–218CrossRefPubMed
53.
Sohn S, Schöffski O, Prinz J, Reich K, Schubert E, Waldorf K, Augustin M (2006) Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 212:137–144CrossRefPubMed
54.
Sticherling M, Augustin M, Boehncke WH, Christophers E, Domm S, Gollnick H, Reich K, Mrowietz U (2011) Therapy of psoriasis in childhood and adolescence—a German expert consensus. J Dtsch Dermatol Ges 9(10):815–823PubMed
55.
56.
Blome C, Gosau R, Radtke MA, Reich K, Rustenbach SJ, Spehr C, Thaci D, Augustin M (2016) Patient-relevant treatment goals in psoriasis. Arch Dermatol Res 308:69–78CrossRefPubMed
57.
Hawro T, Maurer M, Hawro M, Kaszuba A, Cierpialkowska L, Krolikowska M, Zalewska A (2014) In psoriasis, levels of hope and quality of life are linked. Arch Dermatol Res 306:661–666CrossRefPubMedPubMedCentral
58.
Schmitt J, Kuster D (2015) Correlation between dermatology life quality index (DLQI) scores and work limitations questionnaire (WLQ) allows the calculation of percent work productivity loss in patients with psoriasis. Arch Dermatol Res 307:451–453CrossRefPubMed
Metadata
Title
The German National Program on Psoriasis Health Care 2005–2015: results and experiences
Authors
M. Augustin
L. Eissing
A. Langenbruch
A. Enk
T. Luger
D. Maaßen
U. Mrowietz
K. Reich
M. Reusch
K. Strömer
D. Thaçi
R. von Kiedrowski
M. A. Radtke
Publication date
01-08-2016
Publisher
Springer Berlin Heidelberg
Published in
Archives of Dermatological Research / Issue 6/2016
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-016-1637-8

Other articles of this Issue 6/2016

Archives of Dermatological Research 6/2016 Go to the issue

Original Paper

Immunohistochemical study of toll-like receptors 2, 4, and 9 expressions in pemphigus and bullous pemphigoid lesions

Concise Communication

SATB2 is expressed in Merkel cell carcinoma

Concise Communication

Low levels of glutathione are sufficient for survival of keratinocytes after UV irradiation and for healing of mouse skin wounds

Original Paper

Olfactory functions in patients with psoriasis vulgaris: correlations with the severity of the disease

Original Paper

ULBP3: a marker for alopecia areata incognita

Review

Clinical studies in dermatology require a post-treatment observation phase to define the impact of the intervention on the natural history of the complaint